Institutional Investor Sentiment About Fate Therapeutics Inc (NASDAQ:FATE) Improved

Sentiment for Fate Therapeutics Inc (NASDAQ:FATE)

Fate Therapeutics Inc (NASDAQ:FATE) institutional sentiment decreased to 2.1 in Q3 2018. Its down -0.04, from 2.14 in 2018Q2. The ratio has worsened, as 63 hedge funds increased and opened new positions, while 30 decreased and sold stock positions in Fate Therapeutics Inc. The hedge funds in our partner’s database now own: 50.60 million shares, up from 39.35 million shares in 2018Q2. Also, the number of hedge funds holding Fate Therapeutics Inc in their top 10 positions increased from 1 to 2 for an increase of 1. Sold All: 9 Reduced: 21 Increased: 37 New Position: 26.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company has market cap of $1.09 billion. The Company’s immuno-oncology product candidates include FATE-NK100, a natural killer cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. It currently has negative earnings. The companyÂ’s immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders.

The stock decreased 1.29% or $0.22 during the last trading session, reaching $16.82. About 228,646 shares traded. Fate Therapeutics, Inc. (NASDAQ:FATE) has risen 302.15% since January 14, 2018 and is uptrending. It has outperformed by 302.15% the S&P500.

Analysts await Fate Therapeutics, Inc. (NASDAQ:FATE) to report earnings on March, 4. They expect $-0.27 earnings per share, up 6.90 % or $0.02 from last year’s $-0.29 per share. After $-0.31 actual earnings per share reported by Fate Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -12.90 % EPS growth.

Polaris Venture Management Co. V L.L.C. holds 20.17% of its portfolio in Fate Therapeutics, Inc. for 2.47 million shares. Redmile Group Llc owns 10.58 million shares or 5.29% of their US portfolio. Moreover, Endurant Capital Management Lp has 1.48% invested in the company for 204,333 shares. The Luxembourg-based Artal Group S.A. has invested 0.93% in the stock. 683 Capital Management Llc, a New York-based fund reported 649,800 shares.

Since January 1, 0001, it had 1 buying transaction, and 6 sales for $39.16 million activity.

Fate Therapeutics, Inc. (NASDAQ:FATE) Ratings Coverage

Ratings analysis reveals 100% of Fate Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Fate Therapeutics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $17 while the high is $20. The stock’s average target of $18.50 is 9.99% above today’s ($16.82) share price. FATE was included in 2 notes of analysts from August 1, 2018.

Another recent and important Fate Therapeutics, Inc. (NASDAQ:FATE) news was published by Nasdaq.com which published an article titled: “Near-Term Outlook for Equity REIT Stocks Appears Bright – Nasdaq” on January 03, 2019.

Fate Therapeutics, Inc. (NASDAQ:FATE) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.